There’s no escaping the rise of AI adoption and integration. It’s not so much a question of whether you will adopt AI into your business practices, but how.
Value-based care is at the centre of industry discussions at the moment, not only advancing quality and equity in healthcare, but also accelerating innovation in care delivery.
As debate about the usefulness and ethics of generative artificial intelligence (AI) continues, the pharmaceutical industry needs to consider the advantages it can offer, especially for inc
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh